These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946 [TBL] [Abstract][Full Text] [Related]
5. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074 [TBL] [Abstract][Full Text] [Related]
6. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710 [TBL] [Abstract][Full Text] [Related]
7. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983 [TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358 [TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453 [TBL] [Abstract][Full Text] [Related]
11. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Longo F; Russo I; Shimshek DR; Greggio E; Morari M Neurobiol Dis; 2014 Nov; 71():62-73. PubMed ID: 25107341 [TBL] [Abstract][Full Text] [Related]
12. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites. Nirujogi RS; Tonelli F; Taylor M; Lis P; Zimprich A; Sammler E; Alessi DR Biochem J; 2021 Jan; 478(2):299-326. PubMed ID: 33367571 [TBL] [Abstract][Full Text] [Related]
13. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259 [TBL] [Abstract][Full Text] [Related]
14. Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Zhang J; Deng X; Choi HG; Alessi DR; Gray NS Bioorg Med Chem Lett; 2012 Mar; 22(5):1864-9. PubMed ID: 22335897 [TBL] [Abstract][Full Text] [Related]
16. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089 [TBL] [Abstract][Full Text] [Related]
17. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290 [TBL] [Abstract][Full Text] [Related]